STANDARD BIOTLS (LAB)
(Delayed Data from NSDQ)
$1.80 USD
+0.25 (16.13%)
Updated Aug 15, 2024 03:59 PM ET
After-Market: $1.80 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth C Momentum F VGM
Cash flow Statements
Fiscal Year End for Standard BioTools Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -74.66 | -190.10 | -59.24 | -53.02 | -64.79 |
Depreciation/Amortization & Depletion | 15.95 | 15.86 | 16.69 | 18.49 | 18.18 |
Net Change from Assets/Liabilities | 1.79 | -15.48 | -19.93 | 2.41 | -13.24 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 13.63 | 100.35 | 18.42 | 16.70 | 24.64 |
Net Cash From Operating Activities | -43.29 | -89.37 | -44.06 | -15.42 | -35.21 |
Property & Equipment | -2.83 | -3.83 | -13.26 | -12.72 | -2.53 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 1.32 | 15.88 | 0.00 |
Investments | 23.07 | -84.30 | 0.00 | 36.81 | -36.77 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 20.24 | -88.13 | -11.95 | 39.98 | -39.30 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -4.59 | 225.35 | 1.49 | 22.00 | 2.13 |
Issuance (Repayment) of Debt | -2.08 | 18.16 | 9.50 | -0.68 | 1.29 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 6.84 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.14 | -12.76 | -1.87 | -0.46 | -0.63 |
Net Cash from Financing Activities | -6.81 | 230.76 | 15.96 | 20.86 | 2.79 |
Effect of Exchange Rate Changes | 0.03 | -0.40 | -0.02 | 0.39 | 0.06 |
Net Change In Cash & Equivalents | -29.83 | 52.86 | -40.07 | 45.80 | -71.67 |
Cash at Beginning of Period | 82.32 | 29.47 | 69.54 | 23.74 | 95.40 |
Cash at End of Period | 52.50 | 82.32 | 29.47 | 69.54 | 23.74 |
Diluted Net EPS | -0.94 | -2.43 | -0.78 | -0.74 | -0.97 |
Fiscal Year End for Standard BioTools Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -77.88 | -32.16 | -74.66 | -54.88 | -33.88 |
Depreciation/Amortization & Depletion | 4.51 | 2.53 | 15.95 | 11.87 | 7.70 |
Net Change from Assets/Liabilities | -26.52 | -22.50 | 1.79 | 3.40 | 1.71 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -1.63 | -10.36 | 13.63 | 10.39 | 6.67 |
Net Cash From Operating Activities | -101.53 | -62.48 | -43.29 | -29.23 | -17.81 |
Property & Equipment | -2.72 | -0.78 | -2.83 | -2.75 | -1.85 |
Acquisition/ Disposition of Subsidiaries | 280.03 | 280.03 | 0.00 | 0.00 | 0.00 |
Investments | 91.02 | 38.82 | 23.07 | 36.11 | 85.13 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 368.33 | 318.08 | 20.24 | 33.35 | 83.28 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | -39.01 | -10.98 | -4.59 | -4.83 | -4.52 |
Issuance (Repayment) of Debt | -8.19 | -8.19 | -2.08 | -0.83 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.89 | -0.56 | -0.14 | -0.14 | -0.13 |
Net Cash from Financing Activities | -48.09 | -19.73 | -6.81 | -5.81 | -4.64 |
Effect of Exchange Rate Changes | -0.11 | -0.02 | 0.03 | -0.20 | -0.05 |
Net Change In Cash & Equivalents | 218.60 | 235.85 | -29.83 | -1.87 | 60.78 |
Cash at Beginning of Period | 52.50 | 52.50 | 82.32 | 82.32 | 82.32 |
Cash at End of Period | 271.10 | 288.34 | 52.50 | 80.45 | 143.10 |
Diluted Net EPS | -0.12 | -0.27 | -0.24 | -0.27 | -0.22 |